VRDN
Viridian Therapeutics, Inc.\DEMarquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies re-entered | Q3 2024(8Q snapshot) | 7Q | $15 | $16 | +7% |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $14 | $16 | +14% |
| Two Sigma Investments re-entered | Q3 2024(8Q snapshot) | 7Q | $14 | $16 | +14% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $14 | $16 | +14% |
| D.E. Shaw re-entered | Q4 2024(8Q snapshot) | 6Q | $22 | $16 | -26% |
| Point72 Asset Management re-entered | Q4 2024(8Q snapshot) | 6Q | $22 | $16 | -26% |
| AQR Capital Management | Q2 2026(8Q snapshot) | 1Q | $17 | $16 | -4% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Maverick Capital | Q1 2024 | Q1 2026 | → $28 | +52% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Viridian Therapeutics, Inc.\DE. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from May 13, 2026 — the most recent Form 4 on file — not from today.
- Form 40001104659-26-060294May 13, 2026
- Form 4/Aamend0001193125-26-099023Mar 9, 2026
- Form 4/Aamend0001193125-26-099014Mar 9, 2026
- Form 4/Aamend0001193125-26-099008Mar 9, 2026
- Form 4/Aamend0001193125-26-099007Mar 9, 2026
- Form 40001193125-26-092074Mar 4, 2026
- Form 40001193125-26-092071Mar 4, 2026
- Form 4/Aamend0001193125-26-092068Mar 4, 2026
- Form 4/Aamend0001193125-26-092065Mar 4, 2026
- Form 40001193125-26-092040Mar 4, 2026
- Form 40001193125-26-092036Mar 4, 2026
- Form 40001193125-26-092028Mar 4, 2026
- Form 40001193125-26-001097Jan 2, 2026
- Form 40001104659-25-102606Oct 27, 2025
- Form 40000950170-25-093118Jul 2, 2025
Fundamentals
XBRL · Viridian Therapeutics, Inc.\DEAnnual figures sourced directly from Viridian Therapeutics, Inc.\DE's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Viridian Therapeutics, Inc.\DE — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventJun 3, 2026
- 8-KMaterial eventMay 28, 2026
- 8-KMaterial eventMay 26, 2026
- 8-KMaterial eventMay 11, 2026
- 8-KMaterial eventMay 5, 2026
- 10-QQuarterly reportMay 5, 2026
- 8-KMaterial eventMay 5, 2026
- DEF 14AProxy statementApr 17, 2026
- 8-KMaterial eventMar 30, 2026
- 10-KAnnual reportFeb 26, 2026
- 8-KMaterial eventFeb 26, 2026
- 10-QQuarterly reportNov 5, 2025
- 8-KMaterial eventNov 5, 2025
- 8-KMaterial eventOct 23, 2025
- 8-KMaterial eventOct 21, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Two Sigma Investments | Q2 2026 | open | $17 | $16 | -4% |
| AQR Capital Management | Q2 2026 | open | $17 | $16 | -4% |
| Renaissance Technologies | Q2 2026 | open | $17 | $16 | -8% |
| D.E. Shaw | Q1 2026 | open | $28 | $16 | -43% |
| Point72 Asset Management | Q1 2026 | open | $28 | $16 | -43% |
| Point72 Asset Management | Q2 2025 | Q4 2025 | $13 | $29 | +128% |
| D.E. Shaw | Q4 2024 | Q3 2025 | $22 | $18 | -15% |
| Point72 Asset Management | Q4 2024 | Q1 2025 | $22 | $16 | -24% |
| Citadel Advisors | Q3 2024 | open | $14 | $16 | +14% |
| Two Sigma Investments | Q3 2024 | Q1 2026 | $14 | $28 | +100% |
| Millennium Management | Q3 2024 | open | $14 | $16 | +14% |
| Renaissance Technologies | Q3 2024 | Q3 2025 | $15 | $19 | +25% |
| Maverick Capital | Q1 2024 | Q1 2026 | $18 | $28 | +52% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.